论文部分内容阅读
有学者认为副结核分支杆菌在克隆病的发病机制中起重要作用,而予抗结核化疗可能对病程有有利影响。研究旨在观察并评价对克隆病作化疗后的近期和远期疗效。 方法:患者随机分为2组,基本情况及克隆病活动指数具可比性。除予传统治疗外,治疗组予三联抗结核治疗(利福平、异烟肼、乙胺丁醇),另一组予安慰剂对照。所有患者自进入研究日起随访5年。随访记录复发次数、手术治疗次数及部位、住院治疗次数、克隆病活动指数、血液生化指标及疾病活动分数。在第36、48、60个月时对两组进行比较。
Some scholars believe that Mycobacterium paratuberculosis plays an important role in the pathogenesis of Crohn’s disease, and anti-tuberculosis chemotherapy may have a beneficial effect on the course of the disease. The aim of the study was to observe and evaluate the efficacy of clonopathy in the immediate and long term after chemotherapy. Methods: The patients were randomly divided into two groups, the basic situation and clone disease activity index comparable. In addition to traditional treatment, the treatment group triple anti-TB treatment (rifampicin, isoniazid, ethambutol), and the other placebo-controlled. All patients were followed up for 5 years from the study date. Follow-up records of the number of recurrences, the number of surgical treatment and site, the number of hospitalizations, Crohn’s disease activity index, blood biochemical indicators and disease activity scores. The two groups were compared at 36, 48, and 60 months.